Main menu

Ruth Faden and her colleagues, who were part of an Institute of Medicine committee, examine the ethics of postmarketing research in a New England Journal of Medicine essay. Back in 2008, the US Food and Drug Administration told GlaxoSmithKline to look into whether its drug Avandia (rosiglitazone) was associated with a higher risk of heart attack and death as compared to placebo or other, unrelated drug therapies.